Heron Therapeutics gets FDA approval for ZYNRELEF indication expansion covering 13M annual procedures

HERON THERAPEUTICS, INC. /DE/

FDA approved supplemental NDA for ZYNRELEF to include soft tissue and orthopedic surgical procedures, including foot and ankle.
Expanded indication now covers an estimated 13 million procedures annually, an 86% increase over prior indicated procedures.
No unique safety issues identified in new clinical trials for cesarean section, spinal surgery, augmentation mammoplasty, and total shoulder arthroplasty.
CEO Craig Collard highlights label expansion, CrossLink partnership, and potential VAN approval as transformative for ZYNRELEF.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.